Skip to content
S8194Senate2021-2022 SessionSame asA9265

Require Step Therapy Denial Notices

Official title

“Requires notice of adverse step therapy determinations”

Sponsor Neil D. BreslinSD-44+1 co-sponsorAffects Finance
Status
In Senate Committee
Insurance
Impact
4/10
Low
Passage
0%

Bill progress

Step 2 of 7

In committee · Insurance

What's happening

This bill requires insurers and health plans to provide detailed written notice, including appeal instructions, when denying step therapy override requests.

Why it matters

  1. Empowers patients and doctors. By requiring insurers to provide the clinical rationale and alternative medication options when denying step therapy override requests, patients and their health care providers gain clearer insight into why coverage was denied and what other options are available.

  2. Improves appeals process transparency. Detailed, written instructions on both standard and expedited appeals, as well as external appeals, ensure that patients are better informed about their rights and the steps they can take to challenge adverse determinations.

  3. Promotes timely access to care. By mandating that notices include all information necessary for an appeal, the bill aims to prevent unnecessary delays caused by incomplete or unclear denial letters, which can be critical for patients in need of prompt treatment.

  4. Holds insurers and review agents accountable. The legislation establishes enforceable standards for communication, making it harder for insurance companies or utilization review agents to issue vague or insufficient denial notices, thus supporting consumer protections.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Require Step Therapy Denial Notices

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Neil D. Breslin

Senator · Senate District 44

Chair, Insurance

1 Co-sponsor

History

  1. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A9265Assembly

Require Denial Notice Details

In Assembly Committee · Insurance · Sponsor John T. McDonald III

Impact 4 · Low0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8194

IN SENATE

February 1, 2022

Introduced by Sen. BRESLIN -- read twice and ordered printed, and when printed to be committed to the Committee on Insurance

AN ACT to amend the insurance law and the public health law, in relation to requiring notice of adverse step therapy determinations

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subsection (a) of section 4902 of the insurance law is amended by adding a new paragraph 14 to read as follows:

(14) Establishment of a written procedure to assure that the notice of an adverse determination in relation to a step therapy protocol override determination request includes:

(i) the reasons for the determination including the clinical rationale, if any;

(ii) instructions on how to initiate standard and expedited appeals pursuant to section four thousand nine hundred four of this article and an external appeal pursuant to section four thousand nine hundred fourteen of this article;

(iii) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal.

§ 2. Section 4903 of the insurance law is amended by adding a new subsection (e-1) to read as follows:

(e-1) Notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination request shall be made in writing to the insured or the insured's authorized representative and the insured's prescribing health care professional as defined in subsection (f) of section forty-nine hundred of this chapter, and shall include:

(i) the reasons for the determination including the clinical rationale, if any;

(ii) instructions on how to initiate standard and expedited appeals pursuant to section four thousand nine hundred four of this article and

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD14434-01-2

an external appeal pursuant to section four thousand nine hundred fourteen of this article;

(iii) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal.

§ 3. Subdivision 1 of section 4902 of the public health law is amended by adding a new paragraph (l) to read as follows:

(l) Establishment of a written procedure to assure that the notice of an adverse determination in relation to a step therapy protocol override determination request includes: (i) the reasons for the determination including the clinical rationale, if any; (ii) instructions on how to initiate standard and expedited appeals pursuant to subdivision two of section forty-nine hundred four of this title and an external appeal pursuant to section forty-nine hundred fourteen of this article; (iii) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal.

§ 4. Section 4903 of the public health law is amended by adding a new subdivision 5-a to read as follows:

5-a. Notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination request shall be made in writing to the enrollee or the enrollee's authorized representative and the enrollee's prescribing health care professional as defined in subdivision six of section forty-nine hundred of this title, and shall include:

(a) the reasons for the determination including the clinical rationale, if any;

(b) instructions on how to initiate standard and expedited appeals pursuant to section forty-nine hundred four of this title and an external appeal pursuant to section forty-nine hundred fourteen of this article;

(c) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal.

§ 5. This act shall take effect on the ninetieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the insurance law and the public health law, in relation to requiring notice of adverse step therapy determinations

Purpose or general idea of bill

The purpose of this bill is to require notice of an adverse determi- nation related to a step therapy protocol override determination request to the patient and their prescribing healthcare professional.

Summary of provisions

Section one amends section 4902 of the insurance law by adding a new paragraph (14) that establishes a written procedure for the notice of an adverse determination related to a step therapy protocol override deter- mination request includes certain criteria. The bill explicitly states the request must include the reasons for the determination including the clinical rationale. In addition, it requires instructions on how to initiate standard and expedited appeals. Finally, it requires informa- tion that includes any applicable alternative covered, the clinical review criteria relied upon, and any additional necessary information the utilization review agent relied upon to render such decision.

Section two amends section 4903 of the insurance law to require the aforementioned notice of an adverse determination made by a utilization review agent related to a step therapy protocol override determination request. Such notice is required to be made in writing to the insured or their agent and their prescribing healthcare professional. The notice must include the written procedure as required in section one.

Section three amends section 4902 of the public health law with the same required written procedure guidelines as section one.

Section four amends section 4903 of the public health law with the same notice requirements for enrollees as section two.

Section five establishes the effective date, 90 days after it shall become law.

Justification

Providing information on step therapy protocols allows patients to make informed decisions when selecting a health plan. It also allows patients and health care professionals to more easily request step therapy over- rides and appeals and plan for efficient treatment.

Prior legislative history

New Bill

Fiscal implications

None

Effective date

This act shall take effect on the ninetieth day after it shall become law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.